Experiences on ongoing cancer immunotherapy with Nivolumab, Pembrolizumab and Ipilimumab: Insights from patients and oncology healthcare professionals in South Wales, UK - CONVERIS Research Information System by Thomson Reuters:

Go to Header Go to Navigation Go to Content Go to Footer

Title: Experiences on ongoing cancer immunotherapy with Nivolumab, Pembrolizumab and Ipilimumab: Insights from patients and oncology healthcare professionals in South Wales, UK

Funder
Macmillan Cancer Support

Principal Investigator

Watts, Tessa

Project Details

Net value award figure for Cardiff University: £54,201.00

Start date: 01/12/2019

End date: 31/10/2023

Our policy towards the use of cookies